作者
Pascal Amedro,Arthur Gavotto,Antoine Legendre,Kathleen Lavastre,Charlène Bredy,Grégoire De La Villeon,Stéfan Matecki,D. Vandenberghe,Manon Ladeveze,Fanny Bajolle,Gilles Bosser,Hélène Bouvaist,P. Brosset,Laurence Cohen,Sarah Cohen,Sonia Corone,Claire Dauphin,Yves Dulac,Sébastien Hascoët,Xavier Iriart,Magalie Ladouceur,Loı̈c Macé,Oxana-Anca Neagu,Caroline Ovaert,Marie‐Christine Picot,Laurent Poirette,Frederique Sidney,Camille Soullier,Jean-Benoît Thambo,Nicolas Combes,Damien Bonnet,Sophie Guillaumont
摘要
Background Advances in congenital heart disease (CHD) have transferred the mortality from childhood to adulthood. Exercise capacity in young patients with CHD remains lower than in the general population, resulting in deconditioning and impaired quality of life. Evidence based-medicine in cardiac rehabilitation in this age group with CHD remains limited. We present the QUALI-REHAB study rationale, design and methods. Methods The QUALI-REHAB trial is a nationwide, multicentre, randomised, controlled study, aiming to assess the impact of a combined centre and home-based cardiac rehabilitation program on the quality of life of adolescents and young adults (13 to 25 years old) with CHD. Patients with a maximum oxygen uptake (VO2max) < 80% and/or a ventilatory anaerobic threshold (VAT) < 55% of predicted VO2max, will be eligible. Patients will be randomised into 2 groups (12-week cardiac rehabilitation program vs. controls). The primary outcome is the change in the PedsQL quality of life score between baseline and 12-month follow-up. A total of 130 patients are required to observe a significant increase of 7 ± 13.5 points in the PedsQL, with a power of 80% and an alpha risk of 5%. The secondary outcomes are: VO2max, VAT, stroke volume, clinical outcomes, physical and psychological status, safety and acceptability. Conclusion After focusing on the survival in CHD, current research is opening on secondary prevention and patient-related outcomes. The QUALI-REHAB trial intends to assess if a combined centre and home-based rehabilitation program, could improve the quality of life and the exercise capacity in youth with CHD. Trial registration: Clinicaltrials.gov (NCT03690518).